Mr. Swirsky was most recently President, CEO and a director of GenVec, Inc., a publicly-traded biotechnology company, a position he held from 2013 through the sale of the company in 2017. He joined GenVec in 2006 as Chief Financial Officer. Prior to joining GenVec, Mr. Swirsky was a Managing Director and the Head of Life Sciences Investment Banking at Stifel Nicolaus from 2005 to 2006 and held investment banking positions at Legg Mason from 2002 until Stifel Financial's acquisition of the Legg Mason Capital Markets business in 2005. He has also previously held investment banking positions at UBS, PaineWebber and Morgan Stanley. Mr. Swirsky is on the board of directors of Fibrocell Science, Inc., Cellectar Biosciences, Inc., and Pernix Therapeutics Holdings, Inc.  Mr. Swirsky is a certified public accountant and a CFA® charter holder.  He received his B.S. in Business Administration from Boston University and his M.B.A. from the Kellogg School of Management at Northwestern University.

Ely Benaim, M.D. has more than 25 years of experience in healthcare including 15 years of clinical research experience in academia, government and pharmaceutical industry as well as extensive experience in global regulatory affairs. Dr. Benaim was most recently Senior Vice President of Regulatory Affairs & Chief Medical Officer of Berg Pharma. Prior to joining Berg Pharma, Dr. Benaim was Global Clinical Development Leader at Millennium/Takeda Pharmaceuticals where he oversaw global clinical development of the Aurora A kinase inhibitor program. Prior to joining Takeda in 2011, Dr. Benaim served as Vice President of Clinical Affairs for Sangamo BioSciences where he lead the development of zinc-fingers transcription factors cellular therapies in the areas of Cancer, Diabetes, Neurology, Cardiovascular and HIV. Before Sangamo, Dr. Benaim served at Amgen as Global Clinical Lead for the development of rilotumumab, a hepatocyte growth factor antibody for solid tumors, currently in late stage development. Prior to Amgen he was a Senior Director, Oncology Clinical Development at Salmedix/Cephalon Inc. (now Teva, Inc.) where he led the development of TREANDA® to a Phase 3 pivotal trial for lymphoma. Dr. Benaim received his M.D. from the Universidad Central de Venezuela, Caracas and completed his pediatric residency training at the University of South Florida. He completed fellowships in pediatric oncology and bone marrow transplantation at St. Jude's Children's Research Hospital, in Memphis, Tennessee. From 1997 to 2004, he was Assistant Professor in the Department of Pediatrics at the University of Tennessee and an Assistant Member to the Department of Hematology/Oncology. As a member of the Transplantation and Gene Therapy program he published several manuscripts on the areas of stem cell transplantation, immunology and gene therapy. Dr. Benaim also has a passion for global pediatric cancer awareness and care and has been awarded for his contributions in Latin America and the United States.

Lisa Nolan, Ph.D. joined Rexahn as Chief Business Officer in July 2016. Dr. Nolan previously served as Chief Business Officer at Relmada Therapeutics.  Prior to this, she was Managing Director of Nolex Advisors, LLC, where she led successful competitive processes for out-licensing of early and late-stage pharmaceutical products.  Over the course of her career, Ms. Nolan has held various leadership roles at biopharmaceutical companies including Chief Business Officer at Topigen Pharmaceuticals, where she championed and led the acquisition of Topigen by Pharmaxis.  Additionally, she served as Vice President, Global Business Development and Strategic Marketing for SkyePharma Inc., where she completed over a dozen out-licensing deals in the U.S. and Europe with deal values ranging in excess of $500 million.  Ms. Nolan holds a Ph.D. in clinical pharmacology and a M.Sc., and B.Sc., in pharmacy from Trinity College in Dublin, Ireland.

Andrew Eisen, MD, PhD, joined Rexahn Pharmaceuticals in late 2017.  He is a Translational Medicine physician-scientist with 20 years of industry experience that spans preclinical to clinical drug development activities.  Dr. Eisen earned his graduate degrees are from the University of Pennsylvania and trained at Children’s Hospital of Philadelphia and the NIH. He is board-certified in pediatrics and had advanced training in clinical genetics, molecular biology and “omics” methods. He was an Assistant Professor of Pediatrics and Molecular Genetics at The Albert Einstein College of Medicine before entering the biotechnology/pharma sector. Dr. Eisen started, staffed, ran and partnered the Metabolic Diseases Program at CuraGen Corp. with Bayer, AG.  In this program his team help put over 40 novel genomics-derived targets through HTS. Subsequently, Dr. Eisen served as Director of Experimental Medicine at Daiichi-Sankyo Pharma Development followed as Senior Director and leader of the Translational Medicine Group at Eisai Pharmaceuticals. Prior to Rexahn, Dr. Eisen served as Senior Director of Translational Medicine at Acorda Therapeutics.Dr. Eisen has designed, medically managed and developed innovative biomarker strategies applied in FIH to POC clinical trials of small molecules, biologics and antibodies across diverse therapeutic areas that include autoimmunity, cardiovascular, infectious diseases, metabolism, neurology and oncology.


©2018 by Rexahn Pharmaceuticals, Inc. All rights reserved
Rexahn Pharmaceuticals, Inc. - 15245 Shady Grove Road, Suite 455 - Rockville, MD 20850

Terms of Use
Privacy Policy